Dr. Andrea Mastrangelo Explores Unique CD8 T Cell Responses in HIV Controllers | hashtag CROI2025

Dr. Andrea Mastrangelo Explores Unique CD8 T Cell Responses in HIV Controllers | hashtag CROI2025

New research led by Dr. Andrea Mastrangelo at Centre Hospitalier Universitaire Vaudois unveils a distinct transcriptomic signature in lymph node (LN) HIV-specific CD8 T cells of HIV controllers. Unlike chronic HIV-infected individuals (CHI), controllers exhibited an enriched population of stem-like CD8 T cells marked by TCF7, IL7R, and BACH2, which may contribute to proliferative potential and effective viral control.
SGBCC 2025 | Dr. Cynthia Villarreal-Garza: Monitoring and Management of Long-term Toxicities in Young Breast Cancer Patients

SGBCC 2025 | Dr. Cynthia Villarreal-Garza: Monitoring and Management of Long-term Toxicities in Young Breast Cancer Patients

The impact of long-term toxicity management on patient quality of life is increasingly being recognized in breast cancer treatment. At the recently held 19th St. Gallen Breast Cancer Conference (SGBCC 2025), Dr. Cynthia Villarreal-Garza, Director of Clinic Oncology at the Breast Cancer Center, TecSalud,delivered a presentation titled “Ensuring Long-term Healthy Survival of Breast Cancer Patients.” She pointed out that young breast cancer patients, due to the high intensity and long duration of their treatment, face a number of unique toxicity issues that not only affect their physical health but also have a profound impact on their psychological well-being, social functioning, and overall quality of life. To monitor and intervene in these long-term toxicities, Professor Villarreal-Garza proposed the application of “evidence-based approaches for healthy living” and the use of remote monitoring applications to effectively manage toxicities and improve patient quality of life.
Dr. Angela Jia: Rapid Development of Radioligand Therapy, Combined with Local Radiotherapy May Further Improve Survival in Prostate Cancer Patients

Dr. Angela Jia: Rapid Development of Radioligand Therapy, Combined with Local Radiotherapy May Further Improve Survival in Prostate Cancer Patients

Radioligand Therapy (RLT) is an innovative treatment modality in the field of prostate cancer, enriching the therapeutic options. With further research, the personalized application of RLT and its combination with other therapies will become an important direction for the future treatment of prostate cancer. Oncology Frontier invited Dr. Angela Jia, an expert in radiation oncology at the UH Seidman Cancer Center, to share her insights on the role and future potential of RLT and local radiotherapy in the treatment of prostate cancer.
Dr. Zheng Lou: Integrating Traditional and Western Medicine to Overcome the Challenge of Anastomotic Leakage After Low Rectal Cancer Surgery| Annual Meeting of the Chinese Medical Doctor Association’s Colorectal Oncology Committee

Dr. Zheng Lou: Integrating Traditional and Western Medicine to Overcome the Challenge of Anastomotic Leakage After Low Rectal Cancer Surgery| Annual Meeting of the Chinese Medical Doctor Association’s Colorectal Oncology Committee

With changing dietary habits and the increasing adoption of colorectal cancer screening, the incidence of low rectal cancer is on the rise in China. In Shanghai alone, the annual growth rate is estimated at 4.2% to 4.6%, with 70% to 80% of rectal cancers classified as mid-to-low rectal tumors. Despite advancements in surgical techniques, anastomotic leakage remains a critical challenge, with an incidence ranging from 1.6% to 20%. The risk is particularly pronounced in patients who have undergone neoadjuvant chemoradiotherapy, leading to severe complications such as high mortality rates, serious infections, loss of anal function, and an increased risk of tumor recurrence.